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Background: In recent decades, the incidence of cervical cancer and cervical cancer mortality in Austria has
declined by varying degrees. The Pap smear is to be considered a causal factor for this decline.
Methods: This longitudinal analysis is based on a data set of Pap smear assessments collected by the Committee
for Quality Assurance of the Austrian Society of Cytology. Data from 15 laboratories participating in a voluntary
self-monitoring program was analyzed for the time span 2004–2008. The data was analyzed in terms of smear
quality and assessment quality.
A rank-correlation-test for a monotonic trend analysis in the proportion of the three parameters Pap 0, “satisfactory,
but limited/SBL”, and Pap IIID/IV for the timespan 2004 to 2008 was carried out.
Results: For this study, we analyzed an average number of 730,000 smears per year over a five-year period.
Specimens from all but two laboratories, i.e. < 2% of all smears, met the quality criterion for Pap 0 (Bethesda 2001
equivalent: Specimen processed and examined, but unsatisfactory for evaluation of epithelial abnormality), whilst
only four laboratories, i.e. < 10% of all smears, reached the national requirement for smears classified as “satisfactory,
but limited/SBL”.
When using the Pap IIID/IV ratio (LSIL: HSIL/AIS ratio) of 3:1 to 8:1 as a surrogate quality marker for the
interpretation of smears, only five laboratories met this criterion during the survey period.
The trend analysis indicated only that an increasing number of samples per year is correlated with an increased
proportion of Pap 0 and “satisfactory, but limited/SBL” smears.
Conclusions: Although participants get regular feedback about their results, no general improvements in smear
taking or assessment were observed over the years, so mandatory quality management, including the possibility of
sanctions, is suggested in order to reduce adverse health effects for women.
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In recent decades, the incidence of cervical cancer in the
industrialized world, as in Austria, has declined [1]. From
1983 to 2009 the age-standardized incidence declined by
65%, from 19.2 to 6.6 per 100,000 women; in absolute
numbers: from 954 to 394 women [2]. During the same
period, the specific mortality rate dropped by 54% (from
4.4 to 2.0 per 100,000 women; in absolute numbers: from
265 to 141 women). For women aged up to 75, the life-
time prevalence of contracting the disease is 1.9%, and the
risk of dying from it is 0.5% [1]. Between 1980 and 2010* Correspondence: eva.rasky@medunigraz.at
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reproduction in any medium, provided the orthe cumulative likelihood for women aged 15 to 79 of
developing cervical cancer dropped from 2.8% (1.3-2.6
[95% confidence interval]) to 1.0% (0.7-1.6 [95% confi-
dence interval]) [3]. Although a diagnosis of cervical
cancer puts enormous strain on the women affected,
cervical cancer from a public health perspective is actu-
ally not considered to be a major risk for the female
population at large, not least because primary and sec-
ondary preventive measures are available.
The Austrian Federal Ministry of Health recommends,
as a primary preventive measure, the vaccination of both
girls and boys aged between 9 and 12 years against Hu-
man Papillomavirus/HPV [4]. In most Austrian provinces,
the costs for HPV vaccination are borne by the consumer,td. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Rásky et al. BMC Public Health 2013, 13:998 Page 2 of 7
http://www.biomedcentral.com/1471-2458/13/998i.e. generally the parents. Therefore, the vaccination rate in
Austria is only approximately 2–5%, although it varies from
province to province. Experts agree that early detection
measures will still be necessary even after individual HPV
vaccination. For this purpose, smear tests according to
Papanicolaou will remain an important tool. Although the
effectiveness of conventional cytology for cancer screening
has never been tested in randomized studies, the results of
cohort studies are considered to be sufficient proof [5].
Screening should discover dysplasia at an early stage and
with the subsequent interventions morbidity and specific
mortality rates will be reduced.
Austria has been providing Pap smear testing to women
through opportunistic screening since the 1970s [6,7].
Austrian medical societies recommend an annual smear
test for all women from the age of 19, as part of their
gynecological examination [8]. The costs for these exami-
nations are borne by the statutory health insurance as part
of the “new prevention program” regardless of individual
insurance coverage. The Pap smears are mainly taken by
gynecologists in their offices. The taking and assessment
of smears is mostly done using the “conventional” rather
than the “liquid-based” method, because the latter is not
covered by health insurance providers. HPV testing is
funded by statutory health insurances only in certain
specified cases, varying from province to province.
Since the introduction of cancer early detection pro-
grams and in particular since the European Commission
Directive 2003/878/RG regarding screening, quality as-
suring measures have been widely discussed throughout
Europe. The European Union drafted guidelines on quality
assurance [9-11] for screening procedures which, according
to the EU, provide demonstrable benefits. Members of the
European Parliament signed a resolution that the “fight
against cancer” should include program screening [12].
In Austria, the Guideline of the European Commission
recommending program screening with centralized moni-
toring has so far not been implemented [10,13]. Both the
Austrian Society of Cytology and the Austrian Society of
Gynecology and Obstetrics recommend tools for smear
taking and assessment in accordance with the European
Guidelines [14,15]. However, a continuous systematic qual-
ity control is lacking [7]. Only a small number of scientific
articles have hitherto studied the quality of opportunistic
screening in Austria. These publications identified failures
in Pap smear taking as well as in the interpretation of the
smears [16-18]. The results have led the statutory health
insurance providers of some provinces to implement a
number of measures in order to improve Pap smear taking
[19,20]. Furthermore, the Quality Assurance Committee of
the Austrian Society of Cytology initiated a database for
cytology results commencing in 1998. This initiative
aims to improve screening quality [21]. Evaluating the data
sets allows a yearly benchmarking for the participatinglaboratories based on their data concerning Pap smear
taking and interpretation. The guidelines of the Austrian
Society of Cytology require that the laboratories give gyne-
cologists regular quality feedback. Each gynecologist sub-
mitting more than 100 smears annually for testing should
receive a report on the smears taken, comparing them
with the anonymized list of all smear takers using the
cytological laboratory. The reason for introducing this in-
clusion criterion of a minimum of 100 smears is to reduce
statistical variability.
The database of the Austrian Society of Cytology pro-
vides the basis for our first longitudinal analysis of Austrian
data. Evaluating the quality of Pap smear taking and inter-
pretation is important in order to ensure that women re-
ceive reliable results regarding cervical lesions. In addition,
evaluation of the present opportunistic screening provides
baseline data for a program screening in the future. The
longitudinal analysis also allows us to assess the quality
trend over the years. Without improvements in quality
including systematically collecting data the targeted re-
duction in cervix cancer morbidity and mortality can not
be achieved.
Methods
The Quality Assurance Committee of the Austrian Society
of Cytology has been gathering data on Pap smear taking
and assessment since 1998. All cytological laboratories in
Austria are invited to participate in the program. The par-
ticipating cytological laboratories report their data on a
voluntary basis. Although the number of participating la-
boratories increased in recent years, not all laboratories
participate in this voluntary self-monitoring program.
Currently 35 laboratories, i.e. approximately 80% of all
Austrian laboratories, take part [22].
The anonymized data set allow the evaluation of Pap
smear taking and interpretation over an extended period
of time. For our analysis we chose a period of five years:
2004 to 2008. Data for this period existed for 15 (covering
0.73 million smears) of the 35 participating laboratories
(in total 1.03 to 1.65 million smears). These 15 laborator-
ies reported their results annually for at least four years in
the chosen period. This study covers laboratories that
appraised more than 10,000 screening tests each per year.
Pap classification and classification of smear quality
was done in accordance with the national guidelines of the
Austrian Society of Cytology (see the Additional file 1).
Smear quality is given as i) satisfactory, ii) satisfactory, but
limited/SBL, or iii) Pap 0 – unsatisfactory. All three cat-
egories are defined in detail by the Austrian Society of
Cytology [15]. Despite reduced smear quality, e.g. a lack
of endocervical cells or a moderately reduced number of
squamous cells, the second category leaves room for Pap
classification. Although the Austrian quality categories are
similar to the Bethesda 2001 classification, a one-to-one
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equacy is not possible.
As an indicator for the quality of smears, we selected the
proportion of all specimens sent in and those assessed as i)
Pap 0 (Bethesda 2001 best fitting equivalent: Specimen
processed and examined, but unsatisfactory for evaluation
of epithelial abnormality) or ii) “satisfactory, but limited/
SBL”. This indicator is strongly dependent on the quality
of smear taking and is therefore strongly dependent on the
gynecologist taking the smear. On the other hand, the
interpretation of the cytological features with the well-
known intra- and interobserver variability is dependent on
the cytologist, even though variability can be minimized by
using detailed definitions of smear adequacy interpretation
[20]. The quality standard for the indicator as set by the
Austrian Society of Cytology provides for a maximum of
2% Pap 0 classifications (Bethesda 2001 equivalent: Speci-
men processed and examined, but unsatisfactory for evalu-
ation of epithelial abnormality) in relation to all smears
taken [15]. The national standard, also set by the Austrian
Society of Cytology, requires that the category “satisfac-
tory, but limited/SBL” should apply to less than 10% of all
smears taken. Quality improvement was assumed to have
taken place if the number of both classifications decreased
over the survey period. The assumption being that if
appropriate information is given, if smear takers and cyto-
logical appraisers communicate with each other, then
improvement can take place.
In order to evaluate smear interpretation quality we
chose a specific Pap IIID/IV ratio (LSIL : HSIL/AIS ratio)
as quality indicator. It provides a simple surrogate param-
eter for morphologic interpretation, classifying dysplastic
cells as either Pap IIID (LSIL) or Pap IV (HSIL/AIS). This
indicator is strongly dependent on the interpretation of
the cytomorphological features and on the age of the
screened population. This ratio is higher for women under
25 years of age. Although age is a strong confounding fac-
tor with regard to this ratio, we assume that the age distri-
bution of women, whose smears were taken, is rather
similar across the participating laboratories. For this pur-
pose we postulated a benchmark of 3:1 to 8:1, which corre-
sponds to the anticipated natural distribution of low-grade
to high-grade cervical intraepithelial neoplasm/CIN of 4:1
[23]. About 20% of the CIN1 cases progress to CIN2/3,
whilst 80% of all cytologically detected CINs ought to fall
into group Pap IIID and 20% into group Pap IV [24-26]. In
other words, a ratio of 3:1 implies that 75% of all cytologic-
ally detected CINs are classified as Pap IIID (LSIL), and a
ratio of 8:1 implies that 89% are classified as Pap IIID
(LSIL). A German study found Pap IIID (LSIL) in 1.05% of
the smears and Pap IV (HSIL) in 0.135%, which corre-
sponds to a ratio of 8,8:1 [23]. The central point to realize
is reducing the number of CIN2/3 in screened popula-
tions. In this light, a higher ratio seems less problematic. Aratio higher than 8:1 or lower than 3:1 could point to inter-
pretation errors. A limitation of this ratio (Pap IIID/IV)
(LSIL : HSIL/AIS) is that CIN2 is assignable to both the
Pap IIID group (LSIL) and the Pap IV group (HSIL/AIS),
depending on the amount of CIN2 cells found in relation
to low-grade dysplastic cells.
We also carried out a rank-correlation-test in order to
test for a monotonic trend in the proportion of the pa-
rameters Pap 0, “satisfactory, but limited/SBL”, and Pap
IIID/IV for the timespan 2004 to 2008 [27]. Spearman’s
rank correlation was performed between these parame-
ters and the year of evaluation, separately for each la-
boratory. A positive correlation indicates an increase in
the proportion over the five years, whereas a negative
coefficient indicates a decrease. In order to aggregate the
findings of the 15 laboratories, summary statistics (mini-
mum, maximum, median, and inter quartile-range) and a
meta-analysis of the rank-correlation coefficients according
to the random effect model were performed [28]. In this
meta-analysis, the mean correlation coefficient of the 15 la-
boratories and a test for homogeneity among the correla-
tions were calculated. A statistically significant p-value in
this homogeneity test indicates that the correlations ob-
tained from the different laboratories differ in magnitude.
Because the number of samples analyzed in the laboratories
differed from laboratory to laboratory and from year to
year, we also tested for a possible relation between the pro-
portions of the parameters Pap 0, “satisfactory, but limited/
SBL”, and Pap IIID/IV and the number of samples analyzed
per year for the timespan 2004 to 2008. Spearman’s rank
correlation was performed separately for each laboratory
and then aggregated as described above. Finally, a partial
correlation between the proportions of the parameters Pap 0,
“satisfactory, but limited/SBL”, and Pap IIID/IV and the
year of evaluation, was carried out in order to test for a
monotonic trend from 2004 to 2008 while controlling for
the number of samples.
Results
In Austria, with an overall population of 8.4 million, the
potential target population (women over 20 years of age)
is 3.48 million [29]. In the period from 2004 to 2008 gy-
necologists took an estimated average of 2 to 2.2 million
Pap smears per year (personal information from the
Main Association of Austrian Social Security Institu-
tions). These Austrian figures are, however, not precise
because a large number of smears are taken in private
gynecologists’ offices and are thus not counted by the
statutory health insurance. Overall, the 15 selected la-
boratories included in this analysis appraised a total of
730,000 Pap smears on average per year (Table 1),
representing approximately one third of all Pap smears
taken in Austria.
Table 1 Number of Pap smears per laboratory* and year
2004 2005 2006 2007 2008 Total
17,224 10,175 10,941 19,061 17,222 74,623
16,010 15,390 15,318 15,975 14,082 76,775
** 18,282 18,637 19,488 21,655 78,062
16,627 18,258 17,727 17,538 17,542 87,692
** 19,085 22,657 24,607 24,618 90,967
** 10,492 30,150 32,082 31,394 104,118
20,065 20,360 23,829 29,224 33,365 126,843
43,177 40,527 36,546 10,475 ** 130,725
** 47,057 45,095 47,383 48,345 187,880
50,018 47,674 47,672 50,716 56,807 252,887
59,511 59,804 62,862 64,043 65,524 311,744
90,994 95,070 93,233 98,439 ** 377,736
77,712 74,627 74,632 80,108 72,605 379,684
103,403 102,480 102,437 104,032 104,728 517,080
175,171 172,457 170,132 168,697 164,656 851,113
Total 669,912 751,738 771,868 781,868 672,543 3,647,929
*Laboratories were identified by the number of specimens submitted. To
safeguard anonymity the laboratories in Table 1 have no abbreviation, and the
sequence of the laboratories in Tables 1 and 2 has been changed. Despite the
loss of relevant information, this approach was necessary since non-anonymity
might have discouraged laboratories from participating.
**no data available.
Table 2 Percentage of all Pap smears submitted to a
laboratory* that were assessed as Pap 0+ (Bethesda 2001
equivalent: specimen processed and examined, but
unsatisfactory for evaluation of epithelial abnormality)
2004 2005 2006 2007 2008
Lab A 0.17 0.19 0.26 0.29 0.0
Lab B 0.21 0.29 0.15 0.26 0.21
Lab C 0.10 0.10 0.07 0.11 0.09
Lab D ** 0.91 1.08 1.03 0.67
Lab E 0.48 0.45 0.51 0.76 0.91
Lab F 0.17 0.18 0.23 0.17 **
Lab G ** 4.13 2.35 3.74 2.61
Lab H 0.67 0.58 0.50 0.58 1.25
Lab I 0.63 0.65 0.70 0.65 0.09
Lab J 1.62 3.68 3.66 2.21 1.95
Lab K 0.16 0.17 0.69 0.67 0.95
Lab L 0.18 0.26 0.26 0.35 0.16
Lab M 0.07 0.00 0.12 0.07 0.12
Lab N ** 0.02 0.30 0.46 0.40
Lab O ** 0.42 0.43 0.36 0.48
*Laboratories were identified by the number of specimens submitted. To
safeguard anonymity the laboratories in Table 1 have no abbreviation, and the
sequence of the laboratories in Tables 1 and 2 has been changed. Despite the
loss of relevant information, this approach was necessary since non-anonymity
might have discouraged laboratories from participating.
+A national standard, set by the Austrian Society of Cytology, requires that the
category Pap 0 should be less than 2% of all smears taken (15).
**no data available;
Laboratories failing to meet the quality criterion are written in bold.
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from somewhat more than 10,000 to almost 200,000 per
year. Certain individual laboratories had large changes in
the number of smears submitted over the 5-year period,
although half of the laboratories had stable numbers
(Table 1).
Table 2 presents the percentage of all Pap smears sent to
the laboratory and assessed as Pap 0 (“Specimen processed
and examined, but unsatisfactory for evaluation of epithe-
lial abnormality”). All in all, only two out of 15 laboratories
failed to meet the quality standards [15]. Unlike the Be-
thesda classification, the Austrian Pap classification entails
remarks on minor quality deficiencies in an own smear
quality category as “satisfactory, but limited” (SBL). Smears
assessed as SBL still allow Pap classification. However, a
false negative result is more likely in such case, compared
to smears assessed as “satisfactory” [30-32]. When consid-
ering the proportion of specimens that were classified as
SBL a different picture emerges (Table 3). Only four out of
15 laboratories were actually below the required 10% limit
concerning their annual results across all smears submitted
by gynecologists in the survey period. When considering
only those laboratories that supplied data throughout the
entire survey period, only one (out of six) complied with
the national standard. Over the whole period, two of the la-
boratories had even more than 30% of their smears classi-
fied as SBL. The results of the trend analysis for the period
2004 to 2008 showed that no conclusion can be reachedabout a positive or negative trend in relation to lower or
higher proportions of Pap 0 and SBL categories. This is
due to the heterogeneity of laboratory sample sizes and the
proportion of Pap 0 and SBL. Nonetheless, we assumed
that the recommended feedback of cytologists to gynecolo-
gists regarding a possible modification of their smear tak-
ing practice has no influence on quality improvement.
Table 4 presents the Pap IIID/IV ratios (LSIL : HSIL/
AIS ratios) of the specimens sent in to the laboratories.
The surrogate interpretation quality indicator, the Pap
IIID/IV ratio (LSIL: HSIL/AIS ratio) was achieved by five
laboratories. For every given Pap IV (HSIL/AIS), more
than twice the number of Pap IIID (LSIL) was found.
The summary statistics and the test for homogen-
eity of the correlations show, in most cases, a great vari-
ation in trend between the 15 laboratories (Additional
file 1). The averaged correlation between the proportion
of all the three parameters of interest and the year of ob-
servation was rather low (Spearman’s rho ranged from
0.12 to 0.35). There was also little change in magnitude
of the correlation after controlling for the number of
samples. The highest averaged correlations were found
between the proportion of the parameter and the num-
ber of samples analyzed per year for Pap 0 (rho = 0.56)
Table 3 Percentage of all smears submitted to a
laboratory* that were assessed as “satisfactory,
but limited/SBL”+
2004 2005 2006 2007 2008
Lab A 22.94 22.04 21.17 17.50 **
Lab B 18.76 ** 14.02 ** 13.37
Lab C 6.76 8.04 10.90 7.86 7.55
Lab D ** 1.28 2.95 9.08 7.45
Lab E 50.02 54.07 48.35 52.69 46.04
Lab F 5.73 6.90 11.59 9.81 **
Lab G ** 26.15 29.51 28.86 25.00
Lab H 2.39 6.40 7.64 9.05 13.66
Lab I 21.09 21.61 21.59 ** 13.46
Lab J 68.51 45.78 35.70 45.40 38.94
Lab K 4.89 5.49 4.85 4.68 5.57
Lab L 28.96 24.26 25.12 26.61 27.04
Lab M ** ** 16.74 7.81 7.27
Lab N ** 2.16 6.55 9.52 9.24
Lab O ** 2.12 5.05 5.89 7.01
*Laboratories were identified by the number of specimens submitted. To
safeguard anonymity the laboratories in Table 1 have no abbreviation, and the
sequence of the laboratories in Tables 1 and 3 has been changed. Despite the
loss of relevant information, this approach was necessary since non-anonymity
might have discouraged laboratories from participating.
+A national standard, set by the Austrian Society of Cytology, requires that the
category “satisfactory, but limited/SBL” should be less than 10% of all smears
taken (15).
**no data available;
Laboratories failing to meet the quality criterion are written in bold.
Table 4 Pap IIID/IV ratio (LSIL : HSIL/AIS ratio) and
absolute numbers of Pap IIID and IV smears (in brackets)
2004 2005 2006 2007 2008
Lab A 8.76* 5.01 8.57 5.33 **
(394/45) (361/72) (317/37) (128/24)
Lab B 15.09 12.52 10.16 10.56 11.90
(332/22) (288/23) (315/31) (338/32) (595/50)
Lab C 3.85 4.34 6.22 5.23 5.38
(1096/285) (1185/273) (970/156) (904/173) (1087/202)
Lab D ** 3.81 7.75 6.10 7.83
(118/31) (248/32) (354/58) (360/46)
Lab E 7.86 13.60 8.88 9.75 4.07
(55/7) (68/5) (71/8) (78/8) (57/14)
Lab F 4.24 4.48 5.63 5.20 **
(704/166) (695/155) (676/120) (567/109)
Lab G ** 3.36 5.74 4.38 5.66
(131/39) (402/70) (254/58) (362/64)
Lab H 16.13 12.68 13.56 10.23 5.17
(1145/71) (926/73) (1085/80) (982/96) (703/136)
Lab I 2.23 3.08 4.33 4.46 3.72
(1439/644) (1934/628) (1952/451) (1747/392) (1494/402)
Lab J 3.13 0.69 0.51 1.67 2.56
(94/30) (22/32) (18/35) (87/52) (105/41)
Lab K 2.58 1.91 3.18 2.59 3.48
(170/66) (124/65) (226/71) (275/106) (432/124)
Lab L 9.74 5.60 7.00 7.63 6.87
(380/39) (454/81) (441/63) (473/62) (364/53)
Lab M 6.45 3.61 4.37 4.11 5.92
(71/11) (101/28) (131/30) (115/28) (142/24)
Lab N ** 10.60 17.51 14.89 13.80
(1421/134) (1173/67) (1385/93) (1270/92)
Lab O ** 9.87 4.73 21.04 13.75
(464/47) (430/91) (484/23) (495/36)
* read as ratio to 1 for every figure;
** no data available;
The ratios of laboratories falling below the ratio of 3:1 are written in bold.
The ratios of laboratories exceeding the ratio of 8:1 are written in italics.
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indicating that the proportion of Pap 0 and of the
“satisfactory, but limited/SBL” rose as the number of
samples analyzed per year increased. However, a
statistically significant deviation from homogeneity was
found for both parameters, indicating a substantial
variation between the laboratories.
Discussion
The purpose of this analysis was to assess the quality of op-
portunistic screening by evaluating a nationwide data set.
In Austria, only a small number of studies on the quality of
opportunistic Pap screening have been conducted so far
[16-18]. Our study shows again that failures in Pap smear
taking and interpretation of smears exist. We therefore
emphasize the relevance of regular feedback and systematic
data collection, monitoring and evaluation to improve the
quality of Pap screening. Without regular, systematic and
mandatory quality checks adverse effects of screening on
women cannot be assessed. Reducing further cervical
cancer morbidity and mortality will be impossible.
The validity of this study is limited by the fact that not
all Austrian laboratories participate in this voluntary self-
monitoring program initiated and implemented by theAustrian Society of Cytology. Another limiting factor for
the validity of this paper is that only 15 out of the 35 par-
ticipating laboratories regularly reported data in the study
period, meaning they provided data for at least four an-
nual reports and were thus included in this evaluation.
This low level of participation and reporting can be partly
explained by the fact that reporting requires specific
resources and IT support in the laboratories.
Even when accounting for these limitations, the high
proportion of Pap smears assessed as “satisfactory, but
limited/SBL” is particularly alarming. Heterogeneity of
sample sizes across the laboratories and proportions of
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the conclusiveness of the study performed. Trend analysis
only showed that laboratories carrying out a higher num-
ber of smear tests had higher proportions of Pap 0 and
SBL smears, meaning a larger number of gynecologists
failed to meet the quality requirements.
Since the data set is based on voluntary reporting, the
actual number of failures may even be higher than shown
in this evaluation. These deficiencies need to be corrected
as soon as possible. Decision-makers are advised in the
strongest possible terms to take action. In order to assess
and eventually eliminate existing quality deficiencies, man-
datory reporting seems to be an absolute necessity. Statu-
tory health insurance providers should by any means
ensure that their contractual partners (gynecologists and
laboratories) sign a binding agreement concerning their
active involvement in such quality assurance measures.
The best option to start with would be rolling out a tried
and tested model quality assurance project in all Austrian
provinces [19,20]. Workshops on Pap smear quality and
Pap smear taking practice performed in the past effectively
lowered “satisfactory, but limited/SBL” rates over longer
time periods [19].
Given that the surrogate ratio has limitations and that
we have no information on the age of the women of
whom the Pap smears have been taken, deficiencies in
the interpretation of the Pap smear results are evident.
Regarding the IIID/IV ratio (LSIL : HSIL/AIS ratio) under
these premises, our results show shortcomings across the
whole survey period. To enhance assessment quality, health
professionals should be given advanced training. An add-
itional option would be to establish mandatory external
audits for all cytological laboratories evaluating smear tests.
Their participation in monitoring processes should be
remunerated accordingly.
Reimbursing only those services that meet the quality
standards and enhancing continuous and continuing
education of the service providers will not suffice to en-
sure that the European Guidelines are met. These guide-
lines recommend program screening which includes the
definition of a target population, a standardized approach
to smear taking and subsequent diagnostic procedures,
quality standards for the interpretation of smears and
monitoring of the entire screening process, e.g. data col-
lection and analysis. Competing interests of stakeholders
in the field impede the establishing of a standardized pro-
gram for cervical cancer screening. Given the failures in
the present opportunistic screening, there is an urgent
need for action in order to rapidly improve Pap smear tak-
ing in the short term. The longitudinal evaluation shows
that feedback from cytologists to gynecologists regarding
smear taking quality and benchmarking of gynecologists’
smear results on a voluntary basis have not led to changes
in professional behavior. The voluntary self-monitoringprogram in Austria has proven to be insufficient when it
comes to improving quality. There have been no appre-
ciable improvements in any of the measures over the time
period studied and at any individual laboratory. Therefore,
monitoring should take place on a mandatory basis. This
seems to be crucial since due to the low uptake of a
population-wide HPV vaccination Austria currently has
no cohorts of lower-risk young women.
Conclusions
In conclusion and despite the limitations of this study, we
found strong indications concerning the shortcomings of
conventional Pap screening in Austria, in Pap smear taking,
assessment, and in gathering relevant data. It was beyond
the scope of this study to assess how many women have
been harmed by these failures. The real extent of the defi-
ciencies will only become visible upon introducing man-
datory participation for all laboratories and gynecologists.
Sanctions for non-compliant laboratories and gynecologists
are necessary to enforce their adhesion to the quality assur-
ance process. In particular health insurance providers and
the Federal Ministry of Health are called upon, for example
to develop quality indicators and implement effective con-
trolling. It is essential that the Austrian Federal Minister of
Health decree a legally binding federal quality guideline as
the most effective means of addressing the concerns raised
in this study. This standard should also cover the potential
for a future change in cervical screening test from cytology
to a primary HPV test [33-35]. A further delay in taking ac-
tion is harming women with overdiagnosis and overtreat-
ment, or by detecting cervical cancer at a late stage.
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